Zobrazeno 1 - 10
of 75
pro vyhledávání: '"hypomethylating therapy"'
Autor:
Jina Yun, Young Sok Ji, Geum Ha Jang, Sung Hee Lim, Se Hyung Kim, Chan Kyu Kim, Sang Byung Bae, Jong Ho Won, Seong Kyu Park
Publikováno v:
Current Issues in Molecular Biology, Vol 43, Iss 2, Pp 917-931 (2021)
Tet methylcytosine dioxygenase 2 (TET2) is one of the most frequently mutated genes in myelodysplastic syndrome (MDS). TET2 is known to involve a demethylation process, and the loss of TET2 is thought to cause DNA hypermethylation. Loss of TET2 funct
Externí odkaz:
https://doaj.org/article/a575d8a146d547c889df5ce94759502c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sung Hee Lim, Chan Kyu Kim, Jina Yun, Se Hyung Kim, Jong Ho Won, Seong Kyu Park, Sang Byung Bae, Young Sok Ji, Geum Ha Jang
Publikováno v:
Current Issues in Molecular Biology, Vol 43, Iss 65, Pp 917-931 (2021)
Current Issues in Molecular Biology
Volume 43
Issue 2
Pages 65-931
Current Issues in Molecular Biology
Volume 43
Issue 2
Pages 65-931
Tet methylcytosine dioxygenase 2 (TET2) is one of the most frequently mutated genes in myelodysplastic syndrome (MDS). TET2 is known to involve a demethylation process, and the loss of TET2 is thought to cause DNA hypermethylation. Loss of TET2 funct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f1d20213a8dd260c086e9c3797be5d5
https://www.mdpi.com/1467-3045/43/2/65
https://www.mdpi.com/1467-3045/43/2/65
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Identifying novel genetic targets that regulate azacitidine sensitivity in myelodysplastic syndromes
Autor:
Truong, Tuan Kiet Peter
Azacitidine (AZA) and Decitabine (DAC) are frontline hypomethylating agents (HMAs) effective at altering the natural course of Myelodysplastic Syndromes (MDS). Unfortunately, treatment resistance and failure are hallmarks of HMA therapy. Developing e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::40c2da7f587ba6a2eba9bb92ae19fbb9
Autor:
Jörg Cammenga, Albin Österroos, Emma Ölander, Anna Eriksson, Fryderyk Lorenz, Stefan Deneberg, Vladimir Lazarevic, Lovisa Wennström, Petar Antunovic, Gunnar Juliusson, Sören Lehmann, Lars Möllgård, Bertil Uggla, Åsa Derolf, Martin Höglund
Publikováno v:
British Journal of Haematology. 189
Real-world data on treatment patterns and outcomes of hypomethylating therapy in patients with newly diagnosed acute myeloid leukaemia aged >= 60 years
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee9f240a0c8061d9d66122e347c70e81
https://doi.org/10.1111/bjh.16410
https://doi.org/10.1111/bjh.16410
Autor:
Xiubo Fan, Sujoy Ghosh, William Hwang, Subhashree S. Venkatesan, Niraja Dighe, Monalisa Hota, Alice M.S. Cheung, Sudipto Bari, Zhiyong Poon
Publikováno v:
Leukemia
The study of myelodysplastic syndromes (MDS) in murine models has now indicated the possible involvement of the bone marrow microenvironment in the generation of dysplastic hematopoietic cells. However, there is scant work on patient samples and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f6f5dca2cb814c8b2b8fd2a7a2b5490
https://doi.org/10.1038/s41375-018-0310-y
https://doi.org/10.1038/s41375-018-0310-y
Autor:
Rakchha Chhetri, Siddarth Nayar, Michelle Damin, Mithun Vinod Shah, Daniel Thomas, Peter Bardy, Devendra K Hiwase, William Proudman, David M. Ross, Akash Kalro, Kirsty Sharplin, Deepak Singhal, Monika M Kutyna
Publikováno v:
Blood. 138:3702-3702
Introduction: Therapy related myeloid neoplasm (t-MN) is a rare but devastating complication of cytotoxic therapy used for management of unrelated malignancy or autoimmune diseases. Therapeutic options for t-MN are limited and although hypomethylatin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc8dda2962d459350237a20bc5d0d228
https://doi.org/10.1182/blood-2021-154094
https://doi.org/10.1182/blood-2021-154094
Autor:
Wael Saber, Stephen J. Forman, Joseph P. McGuirk, Mary M. Horowitz, Peter Westervelt, Corey Cutler, Sumithira Vasu, Mrinal M. Patnaik, Asmita Mishra, Ryotaro Nakamura, Richard T. Maziarz, Bart L. Scott, Eric S. Leifer, Frederick R. Appelbaum, Michael Martens, Mikkael A. Sekeres, Roni Tamari, Alyssa Ramirez, Betul Oran, Rammurti T. Kamble, Brent R. Logan, Adam M. Mendizabal
Publikováno v:
Transplantation and Cellular Therapy. 27:S2-S3
Background: Recent advances in the treatment of myelodysplastic syndrome (MDS) have improved patient survival and quality of life (QOL), while reducing transfusion burden. However, allogeneic hematopoietic cell transplantation (HCT), widely used in y
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::508fa4538f8c893b7857aa707050ab20
https://doi.org/10.1016/s2666-6367(21)00029-4
https://doi.org/10.1016/s2666-6367(21)00029-4